In a trademark dispute involving diabetes medicines, Novo Nordisk sued Dr Reddy’s Laboratories in the Delhi High Court claiming that the defendant’s use of the mark OLYMVIQ on similar injection products was infringing their registered trademark OZEMPIC and amounted to passing off. During the hearing the defendant immediately agreed to stop all manufacture, sale, promotion and use of OLYMVIQ in any form, withdraw all pending trademark applications for the mark and switch to a new name OLYMRA. The only issues left were the defendant’s existing ready stock of injections and the question of legal costs. The court accepted the defendant’s undertakings, noted that the product was a prescription drug for treating type 2 diabetes with no quality concerns, and allowed the sale of the existing stock within 30 days in the larger public interest; any unsold stock after that period was to be donated to a government hospital in the presence of Novo Nordisk’s representative. The judge also awarded Novo Nordisk 30 per cent of their claimed legal costs after deducting court fees, ordered full refund of the court fees paid, and decreed the entire suit as settled between the parties.
Title: NOVO NORDISK A/S & ANR. Vs. DR REDDYS LABORATORIES LIMITED, Order date: 30.03.2026, Case Number: CS(COMM) 317/2026, I.As. 8033/2026, 8035/2026, 8037/2026, 8039/2026, Neutral Citation: Not provided, Name of court and Judge: IN THE HIGH COURT OF DELHI AT NEW DELHI, HON'BLE MS. JUSTICE JYOTI SINGH.
Disclaimer: Donot treat this as substitute for legal advise as it may contain subjective errors.
Written By: Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi
#IPUpdate #IPCaselaw #IPCaseLaw #IPLaw #IPRNews #IPIndiaupdate #Trademark #Copyright #DesignLaw #PatentLaw #Law #Legal #IndianIPUpdate #AdvocateAjayAmitabhSuman #IPAdjutor
